Pharmacy Operations

How Directors of Pharmacy Build the Business Case CFOs Need for 340B Investment

October 19, 2026

Directors of Pharmacy build a CFO-ready 340B business case by quantifying current program performance, modeling the financial upside of new investment, framing compliance risk in fiscal terms, and proposing a cross-functional structure for ongoing oversight. The strongest cases translate 340B from a compliance topic into a financial and risk-management one that the CFO can understand and already speaks fluently.

Why 340B Investment Now Requires a CFO-Ready Business Case

For years, 340B has lived primarily within pharmacy and compliance departments. However, that’s rapidly changing. Drug spending is rising faster than most other hospital expenses, and CFOs now question every pharmacy-related expense. A compliance argument alone no longer secures funding. The business case needs to speak the CFO’s language: revenue capture, margin protection, and risk measured in dollars. (For a refresher on how the program works, see Understanding the 340B Drug Pricing Program; this article focuses on the CFO conversation, as opposed to the mechanics).

Drug Expense Has Become a C-Suite Issue

Hospital drug expenses per calendar day are up 25% nationally since 2023¹. At hospitals with 500 or more beds, this number has increased by 43.3%². Numbers like that automatically put pharmacy spending on the CFO’s radar, regardless of whether the Director of Pharmacy brings it up first. A 340B program remains one of the real safeguards against that trend and, as such, should be framed as a financial asset, not a compliance function.

Margin Pressure Raises the Stakes for Every Investment Decision

Margins are tightening too, making every discretionary request harder to approve. In hospitals with 26 to 99 beds, operating margins are down 12.3% year over year³. Meanwhile, outpatient revenue has increased 26%, pushing more scrutiny onto line-item charging and J-code accuracy, exactly where a 340B program operates⁴. The CFO weighs these requests against the hospital’s overall financial picture, not the pharmacy’s priorities alone. Frame the request around financial performance, not clinical performance.

Metric	National Trend Since 2023
Drug expense per calendar day	Up 25% overall; up 43.3% at hospitals with 500+ beds (Kaufman Hall NHFR, p. 10, p. 27)
Outpatient revenue	Up 26%, shifting reimbursement toward line-item charging and J-code accuracy (Kaufman Hall NHFR, p. 9)
Purchased services expense	Up 20%, increasing scrutiny of pharmacy-adjacent vendor and platform spend (Kaufman Hall NHFR, p. 10)
Labor expense per calendar day	Up 16% despite moderating cost growth (Kaufman Hall NHFR, p. 10)
Operating margin	Down 12.3% year over year for hospitals with 26-99 beds (Kaufman Hall NHFR, p. 23)

Source: Kaufman Hall National Hospital Flash Report, May 2026 data.

What CFOs Actually Want to See in a 340B Business Case

A boardroom meeting featuring graphs and pie charts on a laptop, with a group of white-coated medical professionals standing and sitting around a boardroom table reviewing information.

Before you build the case, it helps to know what a hospital pharmacy CFO actually screens for. Two things tend to separate a funded proposal from one that gets tabled or dismissed.

Enterprise Data Maturity, Not Just Program Performance

A CFO doesn’t merely want to know the 340B program is saving the hospital money. They want to know how. As in, how fast and how clearly they can report and defend that performance. Financial reporting that draws a clear, traceable line from purchase to dispense to savings signals a mature, low-risk operation. A program that can only produce a quarterly summary is unverifiable, and CFOs are wary of investing more in one, no matter how strong the actual savings are.

Quantified ROI on Dedicated Staffing

Second, a CFO wants a clear comparison between the cost of dedicated 340B staffing and the revenue it protects or unlocks. This is where many internal pitches fail: they describe a workload problem instead of a financial yield. A more effective pitch puts a dollar figure on the savings each additional full-time employee would capture. It adds the cost of relying on one person for program knowledge, including delayed eligibility updates and exposure during a manufacturer or HRSA audit.

How to Build the Business Case Step by Step

With that in mind, here’s the sequence of steps that usually produces a CFO-ready business case.

Start with current-state 340B performance data.

Begin with what the program is doing today, such as savings captured over the last 12 months, covered entity and contract pharmacy performance. Also include any gaps in eligible claims capture. This builds credibility before you ask for anything and gives the CFO a baseline to measure the new investment against, rather than a projection built on assumptions.

Stress-Test the Working Capital Impact of Rebate Models

The 340B program is designed as a point-of-sale discount: the hospital pays the 340B price at the time of purchase. That changes for a small group of drugs on January 1, 2027, when HRSA’s 340B Rebate Model Pilot is scheduled to begin. For drugs in the pilot, the hospital will pay a higher price up front, submit claims data to the manufacturer, and then wait for a rebate covering the difference. Every CFO already understands that gap: it’s cash flow. Estimate how much of your 340B spend the pilot affects and how long rebates may take to arrive, then show how staffing or technology can keep claims submission and reconciliation on schedule. Getting ahead of it now is a real, measurable win for cash position.

Connect Any Tech or Staffing Investment to Risk Mitigation

Each request should point to a specific risk such as: duplicate discounting, gaps in audit trails, or manual processes that can’t keep up with claim volume. Put a dollar amount on that risk, including recoupments, remediation costs, and reputational damage, so that the CFO can weigh it as risk, not as an extra.

Bring a Recommendation, Not Just a Problem

The strongest business cases end with a clear, succinct ask rather than an open-ended one. Propose a cross-functional 340B steering committee that includes pharmacy, finance, compliance, and revenue cycle. That indicates the program is being run as an enterprise asset, not a pharmacy-only issue, and it also gives the CFO a plan they can support with confidence.

Unsure of where your program’s current-state numbers actually stand? A pharmacy performance assessment can give you the baseline data your entire business case depends on. Get a pharmacy assessment.

The Director of Pharmacy’s Role in Championing 340B

Building the case is only half the job. The other half falls to the Director of Pharmacy, who should keep raising these issues in meetings and rooms where 340B isn’t the top priority. That means regular, CFO-friendly updates instead of a one-time pitch, and treating their support as an ongoing relationship, not a single approval. CFOs stay engaged with programs that show steady progress, not ones that only surface at budget time. For more information on building that credibility, consult our Director of Pharmacy Playbook.

How CompleteRx Helps Hospitals Build and Defend Their 340B Business Case

CompleteRx’s strength lies in helping hospitals run their day-to-day pharmacy operations. Unlike the competition, we don’t sell a product roadmap. That’s why our numbers hold up under CFO scrutiny: real savings data from hospital operations and audit reviews that flag issues before HRSA or a manufacturer does. Our 340B consulting services provide you with the data and framework a CFO wants to see.

CompleteRx: Helping You Gain CFO Support

A 340B program doesn’t get funded for merely being compliant. It gets funded and reinvested in because the CFO can see exactly what it returns and how it can protect your hospital. Pharmacy directors who lead with current data, clearly show the working-capital and risk impact, and bring a governance recommendation instead of an open request earn long-term C-suite support. If your baseline data isn’t there yet, that’s the first thing to fix before your next CFO conversation.

Ready to bring your CFO a number, not just a request? Schedule my Assessment

Frequently Asked Questions about How Directors of Pharmacy Build the Business Case CFOs need for 340B Investment.

What is a 340B business case?

A 340B business case is the financial and operational justification a Director of Pharmacy presents to hospital leadership, typically the CFO, to secure investment in 340B staffing, technology, or oversight.

Why does the CFO need to be involved in 340B decisions?

The CFO signs off on 340B-related investment and is financially accountable for the program. Framing 340B in financial terms, not just clinical or compliance terms, is what earns sustained CFO support.

What financial data should a Director of Pharmacy bring to a CFO conversation?

Current-state 340B savings should capture the cost of any staffing gap, and audit or compliance risk in dollar terms rather than policy language.

How does 340B investment affect hospital margins?

Nationally, hospitals are seeing drug expenses rise faster than most other cost categories, while operating margins tighten. A well-run 340B program is one of the few levers that can directly offset that pressure.

What is the difference between 340B compliance and 340B optimization?

Compliance is about meeting program requirements and avoiding audit risk. Optimization, the focus of this piece, focuses on maximizing the financial and operational return of an already compliant program.